321 related articles for article (PubMed ID: 37455226)
1. Effect of the Dual Glucose‐Dependent Insulinotropic Peptide/Gulcagon‐like Peptide 1 Receptor Agonist Tirzepatide on Lipid Profile and Waist Circumference: A Systematic Review and Meta‐analysis.
Yu D; Shen S; Zhang J; Wang Q
Clin Ther; 2023 Aug; 45(8):787-796. PubMed ID: 37455226
[TBL] [Abstract][Full Text] [Related]
2. Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis.
Karagiannis T; Avgerinos I; Liakos A; Del Prato S; Matthews DR; Tsapas A; Bekiari E
Diabetologia; 2022 Aug; 65(8):1251-1261. PubMed ID: 35579691
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
Frias JP; Nauck MA; Van J; Kutner ME; Cui X; Benson C; Urva S; Gimeno RE; Milicevic Z; Robins D; Haupt A
Lancet; 2018 Nov; 392(10160):2180-2193. PubMed ID: 30293770
[TBL] [Abstract][Full Text] [Related]
4. Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials.
Karagiannis T; Malandris K; Avgerinos I; Stamati A; Kakotrichi P; Liakos A; Vasilakou D; Kakaletsis N; Tsapas A; Bekiari E
Diabetologia; 2024 Jul; 67(7):1206-1222. PubMed ID: 38613667
[TBL] [Abstract][Full Text] [Related]
5. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial.
Heise T; Mari A; DeVries JH; Urva S; Li J; Pratt EJ; Coskun T; Thomas MK; Mather KJ; Haupt A; Milicevic Z
Lancet Diabetes Endocrinol; 2022 Jun; 10(6):418-429. PubMed ID: 35468322
[TBL] [Abstract][Full Text] [Related]
6. Tirzepatide, the Newest Medication for Type 2 Diabetes: A Review of the Literature and Implications for Clinical Practice.
Bradley CL; McMillin SM; Hwang AY; Sherrill CH
Ann Pharmacother; 2023 Jul; 57(7):822-836. PubMed ID: 36367094
[TBL] [Abstract][Full Text] [Related]
7. The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect.
Fisman EZ; Tenenbaum A
Cardiovasc Diabetol; 2021 Nov; 20(1):225. PubMed ID: 34819089
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of the dual GIP and GLP-1 receptor agonist tirzepatide for weight loss: a meta-analysis of randomized controlled trials.
de Mesquita YLL; Pera Calvi I; Reis Marques I; Almeida Cruz S; Padrao EMH; Carvalho PEP; da Silva CHA; Cardoso R; Moura FA; Rafalskiy VV
Int J Obes (Lond); 2023 Oct; 47(10):883-892. PubMed ID: 37460681
[TBL] [Abstract][Full Text] [Related]
9. Meta-analysis of head-to-head clinical trials comparing incretin-based glucose-lowering medications and basal insulin: An update including recently developed glucagon-like peptide-1 (GLP-1) receptor agonists and the glucose-dependent insulinotropic polypeptide/GLP-1 receptor co-agonist tirzepatide.
Nauck MA; Mirna AEA; Quast DR
Diabetes Obes Metab; 2023 May; 25(5):1361-1371. PubMed ID: 36700380
[TBL] [Abstract][Full Text] [Related]
10. Tirzepatide: A Review in Type 2 Diabetes.
France NL; Syed YY
Drugs; 2024 Feb; 84(2):227-238. PubMed ID: 38388874
[TBL] [Abstract][Full Text] [Related]
11. Impact of a dual glucose-dependent insulinotropic peptide/glucagon-like peptide-1 receptor agonist tirzepatide on heart rate among patients with type 2 diabetes: A systematic review and pairwise and network meta-analysis.
Yang Y; He L; Liu P; Wang J; Yang N; Li Z; Ping F; Xu L; Li W; Zhang H; Li Y
Diabetes Obes Metab; 2024 Feb; 26(2):548-556. PubMed ID: 37860884
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of high-dose glucagon-like peptide-1, glucagon-like peptide-1/glucose-dependent insulinotropic peptide, and glucagon-like peptide-1/glucagon receptor agonists in type 2 diabetes.
De Block CEM; Dirinck E; Verhaegen A; Van Gaal LF
Diabetes Obes Metab; 2022 May; 24(5):788-805. PubMed ID: 34984793
[TBL] [Abstract][Full Text] [Related]
13. The dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide improves cardiovascular risk biomarkers in patients with type 2 diabetes: A post hoc analysis.
Wilson JM; Lin Y; Luo MJ; Considine G; Cox AL; Bowsman LM; Robins DA; Haupt A; Duffin KL; Ruotolo G
Diabetes Obes Metab; 2022 Jan; 24(1):148-153. PubMed ID: 34542221
[TBL] [Abstract][Full Text] [Related]
14. The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists.
Urva S; Coskun T; Loghin C; Cui X; Beebe E; O'Farrell L; Briere DA; Benson C; Nauck MA; Haupt A
Diabetes Obes Metab; 2020 Oct; 22(10):1886-1891. PubMed ID: 32519795
[TBL] [Abstract][Full Text] [Related]
15. A systematic review of the safety of tirzepatide-a new dual GLP1 and GIP agonist - is its safety profile acceptable?
Meng Z; Yang M; Wen H; Zhou S; Xiong C; Wang Y
Front Endocrinol (Lausanne); 2023; 14():1121387. PubMed ID: 37051199
[TBL] [Abstract][Full Text] [Related]
16. Tirzepatide as a novel effective and safe strategy for treating obesity: a systematic review and meta-analysis of randomized controlled trials.
Cai W; Zhang R; Yao Y; Wu Q; Zhang J
Front Public Health; 2024; 12():1277113. PubMed ID: 38356942
[TBL] [Abstract][Full Text] [Related]
17. Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes.
Thomas MK; Nikooienejad A; Bray R; Cui X; Wilson J; Duffin K; Milicevic Z; Haupt A; Robins DA
J Clin Endocrinol Metab; 2021 Jan; 106(2):388-396. PubMed ID: 33236115
[TBL] [Abstract][Full Text] [Related]
18. Effects of Tirzepatide, a Dual GIP and GLP-1 RA, on Lipid and Metabolite Profiles in Subjects With Type 2 Diabetes.
Pirro V; Roth KD; Lin Y; Willency JA; Milligan PL; Wilson JM; Ruotolo G; Haupt A; Newgard CB; Duffin KL
J Clin Endocrinol Metab; 2022 Jan; 107(2):363-378. PubMed ID: 34608929
[TBL] [Abstract][Full Text] [Related]
19. Potent incretin-based therapy for obesity: A systematic review and meta-analysis of the efficacy of semaglutide and tirzepatide on body weight and waist circumference, and safety.
Müllertz ALO; Sandsdal RM; Jensen SBK; Torekov SS
Obes Rev; 2024 May; 25(5):e13717. PubMed ID: 38463003
[TBL] [Abstract][Full Text] [Related]
20. Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction.
Nauck MA; D'Alessio DA
Cardiovasc Diabetol; 2022 Sep; 21(1):169. PubMed ID: 36050763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
